Cilostazol: Side Effects, Uses & Monitoring
Cilostazol Tablets, USP are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.
- Data source
- FDA labeling via NIH DailyMed (label 151d1497…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Headache | 34% |
| Diarrhea | 19% |
| Abnormal stools | 15% |
| Infection | 14% |
| Rhinitis | 12% |
| Palpitation | 10% |
| Dizziness | 10% |
| Pharyngitis | 10% |
| Peripheral edema | 9% |
| Back pain | 7% |
| Nausea | 7% |
| Dyspepsia | 6% |
| Abdominal pain | 5% |
| Tachycardia | 4% |
| Cough increased | 4% |
| Flatulence | 3% |
| Myalgia | 3% |
| Vertigo | 3% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Cilostazol Tablets, USP are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.
Frequently Asked Questions
What is Cilostazol used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Cilostazol?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Cilostazol. Individual risk varies.
Does Cilostazol require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Cilostazol.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.